摘要
Etelcalcetide(商品名:Parsabiv)是新一代的拟钙剂,与西那卡塞具有相似的作用机制。2017年2月美国FDA批准etelcalcetide用于慢性肾脏病进行血液透析的成年患者继发甲状旁腺功能亢进疾病的治疗。本文对etelcalcetide的作用机制、药效学、药动学、药物相互作用及临床评价等进行综述。
Etelcalcetide hydrochloride is a novel calcimimetic agent that has similar mechanism of action as cinacalcet hydrochloride. It is indicated for secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. The mechanism,pharmacokinetics,and clinical efficacy and safety of etelcalcetide was reviewed in this article. The clinical evidence regarding cinacalcet was summarized to forecast the potential clinical benefits of etelcalcetide.
作者
陈晴
铁远
胡咏川
刘蕾
CHEN Qing;TIE Yuan;HU Yong-chuan;LIU Lei(Beijing Hospital, National Center of Gerontology, Beijing 100730, China;Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University Health Science Center, Beijing 100191, China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2018年第10期1102-1106,共5页
Chinese Journal of New Drugs
